EzraBio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

EzraBio is a private, early-stage biotech firm founded in 2019, developing and commercializing its QEZ-seq® technology for next-generation ribosome profiling. The company operates a hybrid business model, offering complete kits, sequencing services, and data analysis solutions to the research market. Its technology promises to accelerate and improve the accuracy of translational research by bypassing cumbersome sucrose gradient centrifugation, positioning it to capture value in the growing functional genomics and diagnostics tools sector.

DiagnosticsAI / Machine Learning

Technology Platform

QEZ-seq® (Quick and Easy RNA adenylation sequencing) technology for rapid cDNA library preparation from ribosome footprints, eliminating the need for sucrose gradient ribosome separation.

Opportunities

The growing demand for functional genomics tools and the expansion of research into translational control in disease create a significant market for simplified, high-accuracy ribosome profiling.

Integrating AI/ML with its sequencing data could offer a unique, high-value analytical service, creating a recurring revenue stream and deeper customer engagement.

Risk Factors

Key risks include slow adoption by the research community due to entrenched methods, competition from both academic protocols and larger commercial entities, and reliance on external funding as a private, early-stage company with a specialized product in a niche market segment.

Competitive Landscape

EzraBio competes in the ribosome profiling tools market against established academic protocols (e.g., classic Ribo-seq) and reagents from large NGS consumables companies. Its primary differentiation is the elimination of the sucrose gradient step, offering a speed and ease-of-use advantage. It may also face competition from other startups or companies offering alternative translation profiling technologies.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →